Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

International Stem Cell (ISCO) Payables (2016 - 2025)

Historic Payables for International Stem Cell (ISCO) over the last 17 years, with Q3 2025 value amounting to $3.6 million.

  • International Stem Cell's Payables fell 293.64% to $3.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.6 million, marking a year-over-year decrease of 293.64%. This contributed to the annual value of $3.6 million for FY2024, which is 628.11% down from last year.
  • Per International Stem Cell's latest filing, its Payables stood at $3.6 million for Q3 2025, which was down 293.64% from $3.7 million recorded in Q2 2025.
  • In the past 5 years, International Stem Cell's Payables registered a high of $3.9 million during Q2 2024, and its lowest value of $3.4 million during Q2 2021.
  • Its 5-year average for Payables is $3.7 million, with a median of $3.7 million in 2024.
  • In the last 5 years, International Stem Cell's Payables skyrocketed by 85861.11% in 2021 and then tumbled by 628.11% in 2024.
  • Quarter analysis of 5 years shows International Stem Cell's Payables stood at $3.5 million in 2021, then grew by 5.68% to $3.6 million in 2022, then rose by 4.77% to $3.8 million in 2023, then dropped by 6.28% to $3.6 million in 2024, then fell by 0.31% to $3.6 million in 2025.
  • Its Payables stands at $3.6 million for Q3 2025, versus $3.7 million for Q2 2025 and $3.9 million for Q1 2025.